Cost of Revenue Comparison: Gilead Sciences, Inc. vs Biogen Inc.

Cost of Revenue: A Tale of Two Biotech Giants

In the competitive landscape of biotechnology, Gilead Sciences, Inc. and Biogen Inc. have been pivotal players. Over the past decade, from 2014 to 2023, these companies have shown distinct trends in their cost of revenue, a critical metric reflecting the direct costs attributable to the production of their goods.

Gilead Sciences, Inc. consistently outpaced Biogen Inc. in cost of revenue, with figures peaking at approximately $6.6 billion in 2021, a staggering 70% increase from 2014. This growth underscores Gilead's expansive production capabilities and market reach. In contrast, Biogen Inc. exhibited a more modest increase, with its cost of revenue rising by about 116% over the same period, reaching around $2.5 billion in 2023.

These trends highlight the strategic differences in operational scale and market focus between the two biotech titans, offering valuable insights into their financial trajectories.